- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01648153
Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM (T2DM)
A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects With T2DM.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The study will be a randomised, single-blind (sponsor-unblinded), placebo-controlled, study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of repeat intravenous infusions (2 doses 4-weeks apart) of GSK1070806 in obese patients with T2DM. The primary objective of the study will be to assess improvements in fasting and postprandial glucose control. This will be a parallel-group study in 30 obese subjects with T2DM who are poorly controlled on metformin monotherapy (HbA1C>7% but <9.5%), and who have levels of microalbuminuria indicative of progressive kidney disease i.e. 30-300mg/L albumin in urine or ACR ≥3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤30mg/mmol. There will be three treatment groups comprising two active and one placebo arm with 10 subjects per dose group. The study contains a broad range of biomarker assessments, the purpose of which is to evaluate the mechanistic basis by which GSK1070806 exerts its therapeutic benefit in subjects with T2DM.
Subjects will be randomised into one of the three treatment groups where they will receive two intravenous infusions of GSK1070806 or placebo twenty-eight days apart. A MMT challenge will be conducted on Day 1, Day 29, Day 57 and Day 85 for evaluation of the primary endpoints.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Alicante, Espanha, 03004
- GSK Investigational Site
-
Alzira/Valencia, Espanha, 46600
- GSK Investigational Site
-
Granada, Espanha, 18012
- GSK Investigational Site
-
La Roca del Valles (Barcelona), Espanha, 08430
- GSK Investigational Site
-
Lleida, Espanha, 25198
- GSK Investigational Site
-
Madrid, Espanha, 28046
- GSK Investigational Site
-
Madrid, Espanha, 28034
- GSK Investigational Site
-
Malaga, Espanha, 29010
- GSK Investigational Site
-
Málaga, Espanha, 29010
- GSK Investigational Site
-
Petrer, Alicante, Espanha, 03610
- GSK Investigational Site
-
Santander, Espanha, 39008
- GSK Investigational Site
-
-
-
-
-
Cambridge, Reino Unido, CB2 2GG
- GSK Investigational Site
-
Dundee, Reino Unido, DD1 9SY
- GSK Investigational Site
-
-
Warwickshire
-
Birmingham, Warwickshire, Reino Unido, B15 2TT
- GSK Investigational Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- A diagnosis of T2DM as determined by a responsible physician based on a medical evaluation including medical history, physical examination, and laboratory tests, with onset at least 6 months prior to Screening.
- Male or female between 18 and 70 years of age inclusive, at the time of signing the informed consent.
- HbA1c levels ≥ 7.0 % and ≤ 9.5%; at Screening.
- On a stable dose of monotherapy with metformin for three months prior to screening, and at a total daily dose greater than or equal to 1000 mg for at least 2 months prior to dosing.
- Fasting plasma glucose level < 13.3 mmol/L (240 mg/dL) at screening.
- Obese with BMI ≥ 30 kg/m2, and < 40 kg/m2.
- Presence of microalbuminuria: 30-300mg/L albumin in urine or Albumin Creatinine Ratio (ACR) ≥ 3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤ 30 mg/mmol (female and male)..
- The subject is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
A female subject is eligible to participate if she is of:
- Non-childbearing potential
- Child-bearing potential and agrees to use an acceptable form of contraception.
- Male subjects must agree to use one of the contraception methods listed
- ALT < 2xULN; alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Single or Average QTc, QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
Exclusion Criteria:
- Current evidence, or history within the last 7 days, of an influenza-like illness as defined by fever (>38°C) and two or more of the following symptoms: cough, sore throat, runny nose, sneezing, limb / joint pain, headache, vomiting / diarrhoea in the absence of a known cause, other than influenza.
- Use of anti-inflammatory drugs including corticosteroids, chronic maintenance therapy with NSAIDs, anti-Tumor Necrosis Factor (anti-TNF) or anti-Interleukin-1 (anti-IL1) within 60 days prior to dosing.
- Current evidence of ongoing or acute infection, history of repeated, chronic or opportunistic infections (e.g. recurrent folliculitis, other cutaneous infections or repeated pneumonia) or history of a serious bacterial infection within 6 months of randomisation.
- History of malignancy or significant cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions.
- History chronic granulomatous infections, such as of Mycobacterium tuberculosis or any other previous Mycobacterium infection.
- Creatinine clearance less than 60ml/min
- Screens positive of Hepatitis B surface antigen, Hepatitis C antibody or Human Immunodeficiency Virus (HIV)
- History of a severe allergic reaction, anaphylaxis or immunodeficiency.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol screen.
- History of regular alcohol consumption within 6 months of the study
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
- History of sensitivity to any of the study medications, or components thereof
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Pregnant females as determined by positive serum or urine hCG test at screening.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- Subject has received a live attenuated vaccine(s) within 30 days of randomisation or will require vaccination with a live attenuated vaccine prior to the end of the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador Ativo: GSK1070806 0.25mg/kg
TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart
|
To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
|
Comparador Ativo: GSK1070806 5mg/kg
Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart
|
To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
|
Comparador de Placebo: Placebo (Saline)
Two IV administrations of saline 4 weeks apart
|
To compare the efficacy and biomarker changes between placebo and active groups
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Change from baseline in fasting plasma glucose and weighted mean glucose AUC (0-4hrs) post-Mixed Meal Test (MMT)
Prazo: Up to 85 days after the first does
|
To evaluate the efficacy of two repeat intravenous dose administrations of GSK1070806 in subjects with T2DM
|
Up to 85 days after the first does
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Safety and tolerability parameters include: adverse events, clinical laboratory tests, electrocardiograms (ECGs), and vital signs
Prazo: Up to 210 days after the first dose
|
To evaluate the safety and tolerability of two repeat intravenous dose administrations of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Change from baseline in % HbA1c, fasting blood insulin, and C-peptide levels; change from baseline in weighted mean insulin, and C-peptide levels [AUC (0-4hrs)] post-MMT and derived measures of insulin sensitive
Prazo: Up to 85 days after the first dose
|
To evaluate the effect of two repeat intravenous dose administrations of GSK1070806 on additional markers of efficacy, in obese subjects with T2DM
|
Up to 85 days after the first dose
|
AUC(0-τ)
Prazo: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Serum levels of free IL-18 and drug bound IL 18
Prazo: Up to 210 days after the first dose
|
To investigate the effect of repeat intravenous doses of GSK1070806 on free and drug bound IL 18 levels (if measurable) in obese subjects with T2DM.
|
Up to 210 days after the first dose
|
Change from baseline in serum and/or plasma levels of biomarkers of inflammation (e.g. hs-CRP, and IL-6) and metabolic disease (e.g. adiponectin, fructosamine, total cholesterol, high-density lipoprotein (HDL)/low-density lipoprotein (LDL), triglycerides
Prazo: Up to 85 days after the first dose
|
To explore the pharmacodynamic (PD) effect of repeat intravenous doses of GSK1070806 on biomarkers of inflammation and metabolic disease
|
Up to 85 days after the first dose
|
Change from baseline in waist circumference and BMI
Prazo: Up to 85 days after the first dose
|
To investigate the effect of repeat intravenous doses of GSK1070806 on body composition in obese subjects with T2DM
|
Up to 85 days after the first dose
|
Cmax
Prazo: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Tmax
Prazo: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
after the second dose λz
Prazo: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
t1/2
Prazo: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 116378
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Dados/documentos do estudo
-
Especificação do conjunto de dados
Identificador de informação: 116378Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulário de Relato de Caso Anotado
Identificador de informação: 116378Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocolo de estudo
Identificador de informação: 116378Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Plano de Análise Estatística
Identificador de informação: 116378Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Conjunto de dados de participantes individuais
Identificador de informação: 116378Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulário de Consentimento Informado
Identificador de informação: 116378Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Relatório de Estudo Clínico
Identificador de informação: 116378Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em GSK1070806
-
GlaxoSmithKlineConcluídoDermatite AtópicaEstados Unidos, Canadá
-
GlaxoSmithKlineRecrutamentoDermatite AtópicaCanadá, Espanha, China, Estados Unidos, Argentina, Polônia, Republica da Coréia, Panamá, Japão, Bulgária, Tcheca, França, Alemanha, Grécia, Itália, México, Tailândia
-
Cambridge University Hospitals NHS Foundation TrustDesconhecido
-
GlaxoSmithKlineConcluído
-
GlaxoSmithKlineConcluídoDoenças Inflamatórias IntestinaisReino Unido
-
University of BirminghamGlaxoSmithKline; University Hospital BirminghamConcluído
-
Seoul National University HospitalAinda não está recrutandoHipotensão | Complicações Intraoperatórias | Hipotensão Neonatal
-
GlaxoSmithKlineRescindidoTransplante Renal (Posto de Status)Reino Unido, Espanha